Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is pleased to announce that management will be participating in Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Don’t miss this opportunity to hear from Vertex’s leadership team as they provide an insightful overview of the company’s progress and future plans at 2:50 p.m. ET.
Vertex is a pioneering biotechnology powerhouse that seeks to revolutionize the way serious diseases are treated. Through cutting-edge scientific research, the company has developed multiple medicines approved to treat the root cause of cystic fibrosis (CF). Vertex is also actively engaged in a myriad of clinical and research programs in CF and other serious diseases, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy. By pushing the boundaries of biotechnology, Vertex is striving to make life-changing breakthroughs in the fight against serious diseases.
Vertex Pharmaceuticals has been a leader in the biopharmaceutical industry since its founding in 1989 in Cambridge, Massachusetts. Today, its global headquarters are located in the heart of Boston’s Innovation District, and its international headquarters is based in London. But Vertex’s reach extends far beyond that, with research and development sites and commercial offices in North America, Europe, Australia, and Latin America. Its commitment to a thriving workplace is reflected in its numerous accolades, including 13 consecutive years on Science magazine’s Top Employers list, and a spot on Fortune’s Best Workplaces in Biotechnology and Pharmaceuticals and Best Workplaces for Women.